Revive Therapeutics Ltd. (RVVTF)

Revive Therapeutics Income Statement

Financials in millions CAD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Selling, General & Admin	2.1	2.04	1.94	2.68	4.54	2.15
Research & Development	0.69	1.11	3.58	15.16	6.7	0.46
Operating Expenses	2.92	3.29	5.53	17.84	18.57	3.69
Operating Income	-2.92	-3.29	-5.53	-17.84	-18.57	-3.69
Interest Expense	-0.01	-0.02	-0.04	-0.06	-0.08	-0.09
Interest & Investment Income	0.01	0.06	0.11	0.12	0.08	0.05
Other Non Operating Income (Expenses)	-	-	-	-	-	-0.01
EBT Excluding Unusual Items	-2.99	-3.25	-5.46	-17.78	-18.57	-3.73
Gain (Loss) on Sale of Investments	-0.06	-0.05	-0.09	-	0.18	-0.45
Asset Writedown	-2.34	-2.34	-0.78	-	-	-
Other Unusual Items	0.09	0.02	-	-0.03	-1.73	-1.19
Pretax Income	-5.29	-5.62	-6.32	-17.81	-20.12	-5.38
Net Income	-5.29	-5.62	-6.32	-17.81	-20.12	-5.38
Net Income to Common	-5.29	-5.62	-6.32	-17.81	-20.12	-5.38
Shares Outstanding (Basic)	411	380	339	320	267	107
Shares Outstanding (Diluted)	411	380	339	320	267	107
Shares Change (YoY)	15.37%	12.11%	6.13%	19.54%	150.28%	67.08%
EPS (Basic)	-0.01	-0.01	-0.02	-0.06	-0.08	-0.05
EPS (Diluted)	-0.01	-0.01	-0.02	-0.06	-0.08	-0.05
Free Cash Flow	-2.6	-3.29	-6.03	-13.06	-8.31	-2.52
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.04	-0.03	-0.02
EBITDA	-2.92	-3.29	-5.52	-17.84	-18.57	-3.66
D&A For EBITDA	0	0	0	0	0	0.03
EBIT	-2.92	-3.29	-5.53	-17.84	-18.57	-3.69

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.